Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir bulk supplier for pharma manufacturers

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet)

Reference Brands: Viekira Pak® (US); Viekirax® + Exviera® (EU)

Category: Hepatitis

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir, marketed as Viekira Pak® (US) and Viekirax® + Exviera® (EU), is a fixed-dose oral combination for Hepatitis C genotype 1. Approved by FDA and EMA, it offers an effective interferon-free treatment option, often used with ribavirin in B2B supply for global pharmaceutical markets.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is a fixed-dose combination therapy used in the treatment of chronic Hepatitis C genotype 1. Marketed as Viekira Pak® in the US and Viekirax® + Exviera® in the EU, this regimen includes four direct-acting antivirals that target multiple stages of the HCV replication cycle. It offers a non-interferon-based treatment, often in combination with ribavirin. EMA and FDA approved, it’s a key option for B2B pharmaceutical partners sourcing branded and generic HCV therapies. Suitable for hospital, retail, and tender supply in regulated and semi-regulated markets. Available in tablet form with clearly defined daily dosing.

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir — third party manufacturing & bulk supply

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ombitasvir/Paritaprevir/Ritonavir + Dasa... →

Back to Listing

Frequently Asked Questions

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is listed as Tablet in Ombitasvir 12.5 mg / Paritaprevir 75 mg / Ritonavir 50 mg (tablet)+ Dasabuvir 250 mg (tablet). Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir is referenced against Viekira Pak® (US); Viekirax® + Exviera® (EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.